Skip to main content
SpringerLink
Log in

Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review

  • Review Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Background

Cardiovascular autonomic neuropathy (CAN) is a debilitating complication of diabetes mellitus. To date, there is no systematic review on all the available drug treatments for CAN in diabetic patients, except for one review focusing on aldose reductase inhibitors.

Objective

To evaluate available drug treatment options for CAN in diabetic patients.

Methods

A systematic review was conducted with a search of CENTRAL, Embase, PubMed and Scopus from database inception till 14th May 2022. Randomised controlled trials (RCTs) of diabetic patients with CAN that investigated the effect of treatment on blood pressure, heart rate variability, heart rate or QT interval were included.

Results

Thirteen RCTs with a total of 724 diabetic patients with CAN were selected. There was a significant improvement in the autonomic indices of diabetic patients with CAN given angiotensin-converting enzyme inhibitor (ACEI) for 24 weeks (p<0.05) to two years (p<0.001), angiotensin-receptor blocker (ARB) for one year (p<0.05), single dose of beta blocker (BB) (p<0.05), omega-3 polyunsaturated fatty acids (PUFAs) for three months (p<0.05), alpha-lipoic acid (ALA) for four months (p < 0.05) to six months (p=0.048), vitamin B12 in combination with ALA, acetyl L‑carnitine (ALC), superoxide dismutase (SOD) for one year (p=0.001)  and near significant improvement in the autonomic indices of diabetic patients with CAN given vitamin E for four months (p = 0.05) compared to the control group. However, there was no significant improvement in the autonomic indices of patients given vitamin B12 monotherapy (p ≥ 0.05).

Conclusion

ACEI, ARB, BB, ALA, omega-3 PUFAs, vitamin E, vitamin B12 in combination with ALA, ALC and SOD could be effective treatment options for CAN, while vitamin B12 monotherapy might be unlikely to be recommended for the treatment of CAN due to its lack of efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:639–53.

    Article  PubMed  Google Scholar 

  2. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5:17–39.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Migisha R, Agaba DC, Katamba G, Kwaga T, Tumwesigye R, Miranda SL, Muyingo A, Siedner MJ. Prevalence and correlates of cardiovascular autonomic neuropathy among patients with diabetes in uganda: a hospital-based cross-sectional study. Glob Heart. 2020;15:21.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lieb DC, Parson HK, Mamikunian G, Vinik AI. Cardiac autonomic imbalance in newly diagnosed and established diabetes is associated with markers of adipose tissue inflammation. Exp Diabetes Res. 2012;2012: 878760.

    Article  PubMed  Google Scholar 

  6. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 1997;46:S31–7.

    Article  CAS  PubMed  Google Scholar 

  7. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010;33:434–41.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Spallone V. Update on the impact, diagnosis and management of cardiovascular autonomic neuropathy in diabetes: what is defined, what is new, and what is unmet. Diabetes Metab J. 2019;43:3–30.

    Article  PubMed  Google Scholar 

  9. Ko SH, Song KH, Park SA, Kim SR, Cha BY. Cardiovascular autonomic dysfunction predicts acute ischaemic stroke in patients with type 2 diabetes mellitus: a 7-year follow-up study. Diabetes Med. 2008;25:1171–7.

    Article  CAS  Google Scholar 

  10. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40:136–54.

    Article  CAS  PubMed  Google Scholar 

  11. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. J Am Med Assoc. 1997;277:1046–51.

    Article  CAS  Google Scholar 

  12. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358:615–24.

    Article  CAS  PubMed  Google Scholar 

  13. Hu X, Li S, Yang G, Liu H, Boden G. Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: systematic review and meta-analysis. PLoS One. 2014;9: e87096.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Aldose reductase inhibitors. In: Aronson J, editor. Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions. Elsevier Science; 2015. p. 131

  15. Tsai SC, Burnakis TG. Aldose reductase inhibitors: an update. Ann Pharmacother. 1993;27:751–4.

    Article  CAS  PubMed  Google Scholar 

  16. Foppiano M, Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet. 1997;349:399–400.

    Article  CAS  PubMed  Google Scholar 

  17. Prisma,. explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. Br Med J. 2020;2021(372): n160.

    Google Scholar 

  18. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366: l4898.

    Article  Google Scholar 

  19. Athyros VG, Didangelos TP, Karamitsos DT, Papageorgiou AA, Boudoulas H. Long-term effect of converting enzyme inhibition on circadian sympathetic and parasympathetic modulation in patients with diabetic autonomic neuropathy. Acta Cardiol. 1998;53:201–9.

    CAS  PubMed  Google Scholar 

  20. Didangelos TP, Arsos GA, Karamitsos DT, Athyros VG, Georga SD. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complicat. 2006;20:1–7.

    Article  Google Scholar 

  21. Hjortkjær HØ, Jensen T, Kofoed KF, Mogensen UM, Sigvardsen PE. Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping: a randomised, placebo-controlled, double-blind cross-over trial. Br Med J. 2016;6: e012307.

    Google Scholar 

  22. Reid W, Ewing DJ, Harry JD, Smith HJ, Neilson JM. Effects of beta-adrenoceptor blockade on heart rate and physiological tremor in diabetics with autonomic neuropathy. A comparative study of epanolol, atenolol and pindolol. Br J Clin Pharmacol. 1987;23:383–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lee SJ, Jeong SJ, Lee YC, Lee YH, Lee JE. Effects of high-dose α-lipoic acid on heart rate variability of type 2 diabetes mellitus patients with cardiac autonomic neuropathy in Korea. Diabetes Metab J. 2017;41:275–83.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes. 2015;6:80–91.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avramidis MJ. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care. 1997;20:355–61.

    Article  CAS  PubMed  Google Scholar 

  26. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr. 2001;73(6):1052–7.

    Article  CAS  PubMed  Google Scholar 

  27. Serhiyenko VA, Segin VB, Serhiyenko AA. Effects of omega-3 polyunsaturated fatty acids on the circadian rhythm of heart rate variability parameters in patients with type 2 diabetes mellitus and cardiovascular autonomic neuropathy. Russ J Cardiol. 2018;23:56–6021.

    Article  Google Scholar 

  28. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care. 1997;20:369–73.

    Article  CAS  PubMed  Google Scholar 

  29. Kiviniemi AM, Hautala AJ, Seppänen T, Mäkikallio TH, Huikuri HV. Saturation of high-frequency oscillations of R-R intervals in healthy subjects and patients after acute myocardial infarction during ambulatory conditions. Am J Physiol Heart Circ Physiol. 2004;287:H1921–7.

    Article  CAS  PubMed  Google Scholar 

  30. Didangelos T, Tziomalos K, Margaritidis C, Kontoninas Z, Stergiou I. Efficacy of Administration of an angiotensin converting enzyme inhibitor for two years on autonomic and peripheral neuropathy in patients with diabetes mellitus. J Diabetes Res. 2017;2017:6719239.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Avram R, Tison GH, Aschbacher K, Kuhar P, Vittinghoff E. Real-world heart rate norms in the Health eHeart study. NPJ Digit Med. 2019;2:58.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115:387–97.

    Article  PubMed  Google Scholar 

  33. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Pafili K, Trypsianis G, Papazoglou D, Maltezos E, Papanas N. Simplified diagnosis of cardiovascular autonomic neuropathy in type 2 diabetes using ewing’s battery. Rev Diabet Stud. 2015;12:213–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ziegler D, Laux G, Dannehl K, Spüler M, Mühlen H. Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med. 1992;9:166–75.

    Article  CAS  PubMed  Google Scholar 

  36. Srivastav S, Jamil RT, Zeltser R. Valsalva Maneuver. In: StatPearls. StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK537248. Accessed 19 Jun 2022

  37. Agashe S, Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. Methodist Debakey Cardiovasc J. 2018;14:251–6.

    Article  PubMed  PubMed Central  Google Scholar 

  38. DeMers D, Wachs D. Physiology, Mean Arterial Pressure. In: StatPearls. StatPearls Publishing; 2021 https://www.ncbi.nlm.nih.gov/books/NBK538226. Accessed 19 Jun 2022

  39. Brzezinski WA. Blood Pressure. In: Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Butterworths; 1990. https://www.ncbi.nlm.nih.gov/books/NBK268. Accessed 19 Jun 2022

  40. Dadlani A, Madan K, Sawhney JPS. Ambulatory blood pressure monitoring in clinical practice. Indian Heart J. 2019;71:91–7.

    Article  PubMed  Google Scholar 

  41. Rosei EA, Chiarini G, Rizzoni D. How important is blood pressure variability? Eur Heart J. 2020;22:E1-6.

    Article  Google Scholar 

  42. Didangelos T, Karlafti E, Kotzakioulafi E, Kontoninas Z, Margaritidis C. Efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin b12, and carnitine for 12 months in patients with diabetic neuropathy. Nutrients. 2020;12:3254.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Didangelos T, Karlafti E, Kotzakioulafi E, Margariti E, Giannoulaki P. Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind. Placebo-Controlled Trial Nutrients. 2021;13:395.

    CAS  PubMed  Google Scholar 

  44. Serhiyenko VA, Segin VB, Serhiyenko AA. The effect of OMEGA-3 polyunsaturated fatty acids on ambulatory blood pressure monitoring parameters in patients with type 2 diabetes mellitus and cardiovascular autonomic neuropathy. In: Diabetes Mellitus. Endocrinology Research Centre; 2019. https://www.dia-endojournals.ru/jour/article/view/9630?locale=en_US. Accessed 19 Jun 2022

  45. Farzam K, Jan A. Beta Blockers. In: StatPearls. StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK532906. Accessed 19 Jun 2022

  46. Di Gennaro F, D’Amato C, Morganti R, Greco C, Longo S. Morning blood pressure surge is associated with autonomic neuropathy and peripheral vascular disease in patients with diabetes. J Hum Hypertens. 2020;34:495–504.

    Article  PubMed  Google Scholar 

  47. Vasotec label. United States: Food and Drug Administration; 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018998s076lbl.pdf. Accessed 19 Jun 2022

  48. COZAAR. United States: Food and Drug Administration; 2008. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020386s049lbl.pdf. Accessed 19 Jun 2022

  49. TENORMIN. United States: Food and Drug Administration; 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018240s031lbl.pdf. Accessed 19 Jun 2022

  50. Tang Y, Shah H, Bueno Junior CR, Sun X, Mitri J, Sambataro M, Sambado L, Gerstein HC, Fonseca V, Doria A, Pop-Busui R. intensive risk factor management and cardiovascular autonomic neuropathy in Type 2 diabetes: the ACCORD trial. Diabetes Care. 2021;44(1):164–73.

    Article  PubMed  Google Scholar 

  51. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Supplement Appendix 1 to: effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

    Article  Google Scholar 

  52. Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med. 1999;26:1495–500.

    Article  CAS  PubMed  Google Scholar 

  53. Peh HY, Tan WS, Liao W, Wong WS. Vitamin E therapy beyond cancer: tocopherol versus tocotrienol. Pharmacol Ther. 2016;162:152–69.

    Article  CAS  PubMed  Google Scholar 

  54. Lepretti M, Martucciello S, Burgos Aceves MA, Putti R, Lionetti L. Omega-3 fatty acids and insulin resistance: focus on the regulation of mitochondria and endoplasmic reticulum stress. Nutrients. 2018;10(3):350.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106:2747–57.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117559, Singapore

    Jasmine KaiLi Goh & Leroy Koh

Authors
  1. Jasmine KaiLi Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leroy Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jasmine KaiLi Goh.

Ethics declarations

Conflict of interest

There is no conflict of interest by any of the authors.

Human and animal rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 14 KB)

Supplementary file2 (DOCX 20 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goh, J.K., Koh, L. Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review. Diabetol Int 14, 224–242 (2023). https://doi.org/10.1007/s13340-023-00629-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-023-00629-x

Keywords

Search

Navigation